Live Breaking News & Updates on European Renal Association Congress

Stay updated with breaking news from European renal association congress. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Ozempic reduces risk of serious illness and death in people with diabetes and kidney disease, study finds

Weekly injections of semaglutide medications like Ozempic significantly reduce the risk of serious kidney outcomes, major cardiovascular events and death among people who have type 2 diabetes and chronic kidney ....

United-states , Denmark , Sydney , New-south-wales , Australia , Danish , American , Katherine-tuttle , Martin-holst-lange , Vlado-perkovic , European-renal-association-congress , University-of-washington

Helen Colhoun, MD: Semaglutide 2.4 mg (Wegovy) Reduces Kidney Outcomes in SELECT

Helen Colhoun, MD, discusses the results of a SELECT analysis she presented at the 61st European Renal Association Congress. ....

Helen-colhoun , Novo-nordisk , University-of-edinburgh , European-renal-association-congress , Nature-medicine , Medical-informatics ,

Iptacopan Reduces Proteinuria, Demonstrates Benefit in C3 Glomerulopathy

In the APPEAR-C3G trial, iptacopan reduced proteinuria by 35.1% in patients with C3 glomerulopathy, with Novartis planning regulatory submissions for C3G before the end of 2024. ....

Sweden , Stockholm , G-steering-committee-member-david-kavanagh , Novartis , European-renal-association-congress , Foundation-trust-david-kavanagh , Faculty-of-medical-sciences-at-newcastle-university , David-kavanagh , Steering-committee-member-david-kavanagh , Complement-therapeutics , Honorary-consultant-nephrologist

Pegcetacoplan Offers Potential Benefit in Post-Transplant C3G, IC-MPGN

The phase 2 NOBLE trial shows pegcetacoplan reduces disease activity in post-transplant C3G and IC-MPGN, with benefits persisting through the 40-week double-blind period. ....

Stockholm , Sweden , United-states , American , Fadi-fakhouri , Caroline-baumal , European-renal-association-congress , University-of-lausanne-fadi-fakhouri , Apellis-pharmaceuticals-inc , Lausanne-university-hospital , American-society-of-nephrology-kidney-week , Lausanne-university

David Kavanagh, MBChB, PhD: Iptacopan Offers Hope for C3 Glomerulopathy

A Q&A with David Kavanagh, MBChB, PhD, on the results of the APPEAR-C3G trial and implications for care moving forward. ....

Stockholm , Sweden , David-kavanagh , European-renal-association-congress , Faculty-of-medical-sciences-at-newcastle-university , Foundation-trust-david-kavanagh , Novartis , Complement-therapeutics , Honorary-consultant-nephrologist , Medical-sciences , European-renal-association ,